New FDA-Approved Cancer Pill Stuns Oncologists

A daily pill just gave pancreatic cancer patients something this disease rarely offers: more time.

Quick Take

The Food and Drug Administration (FDA) approved daraxonrasib, brand name Rasonque, on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma.
In a 500-patient trial, the drug nearly doubled median survival, from 6.7 months to 13.2 months compared to standard chemotherapy.
The approval covers patients who already tried at least one prior treatment or cannot handle multi-drug chemotherapy.
Regulators call it the first targeted therapy of its kind for this specific, hard-to-treat form of pancreatic cancer.

What The FDA Actually Approved

The FDA approved daraxonrasib for a specific group of patients: adults with metastatic pancreatic adenocarcinoma who already received one round of systemic therapy, or who cannot tolerate multiagent chemotherapy. This is not a blanket cure-all for pancreatic cancer. It targets a narrow, previously treated population, which matters because pancreatic cancer is usually caught late and treated aggressively from the start.

Revolution Medicines, the company behind the drug, developed daraxonrasib as an oral inhibitor targeting the RAS protein family, a group of genes long tied to aggressive tumor growth. The company and the FDA both describe it as the first targeted cancer medicine approved from this entirely new drug class. For a disease that has seen few real advances in decades, that distinction carries weight.

The Numbers Behind The Headline

The approval rested on a randomized, open-label trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. Patients taking daraxonrasib lived a median of 13.2 months, compared to 6.7 months for those on standard chemotherapy. Doubling survival time in a cancer this deadly is a rare result, and it explains why the FDA moved this drug through its pipeline faster than usual.

That speed did not happen overnight. The FDA granted daraxonrasib Breakthrough Therapy designation back in June 2025, a status reserved for drugs showing early, substantial promise over existing options. The agency also cleared an expanded access program in May 2026, letting some patients use the drug before formal approval. Each step signaled growing confidence long before the final green light.

A Longer Regulatory Path That Led Here

Daraxonrasib picked up Orphan Drug Designation in October 2025, a status for treatments targeting rare or hard-to-treat diseases, followed by formal application acceptance in July 2026. That steady sequence, from orphan status to breakthrough designation to full approval, reflects how the FDA handles drugs it views as filling a real gap in cancer care, rather than a rushed or unusual shortcut.

Pancreatic cancer has long resisted this kind of progress. A separate targeted drug, zenocutuzumab, won accelerated approval in December 2024, but only for a rare genetic subtype involving NRG1 gene fusions, a much smaller slice of patients. Daraxonrasib’s approval reaches a broader group defined by RAS-related biology, which is far more common in pancreatic tumors, making its potential reach considerably wider.

What Comes Next For Patients And Doctors

Approval does not mean instant access. Pricing and insurance coverage decisions still have to follow, and those talks often determine how quickly a new drug actually reaches patients in doctors’ offices. Oncologists will also need time to work daraxonrasib into treatment plans alongside existing chemotherapy options, especially for patients who are frail or have already been through multiple rounds of treatment.

💊💉 A historic breakthrough in the fight against cancer.

The US FDA has granted expedited approval to "Rasonque" (daraxonrasib), a groundbreaking once-daily pill from Revolution Medicines that nearly doubles the survival time for patients with advanced pancreatic cancer. ♋️… pic.twitter.com/E9bSGdBuw8

— Mazi okwuoma (@MaziEzike_Nedu) August 27, 2026

Pancreatic cancer has one of the lowest survival rates of any major cancer, which is exactly why this approval carries so much emotional and medical weight. A drug that nearly doubles median survival, backed by a 500-patient randomized trial and years of regulatory vetting, represents genuine, measurable progress. Patients and families dealing with this disease finally have a new tool grounded in real trial data, not just hope.